Le Lézard
Classified in: Health, Science and technology
Subjects: Photo/Multimedia, Product/Service

Mercy St. Louis Begins Treatment With Mevion Compact Proton Therapy System


Mevion Medical Systems, the leading provider of compact proton therapy systems for use in radiation treatment for cancer patients, announced today that the first patient was treated at the David C. Pratt Cancer Center at Mercy Hospital St. Louis on July 5th with the MEVION S250i Proton Therapy System®.

The new Mercy Proton Therapy Center is one of only 40 treating centers in the U.S. Thanks to the compact size of the MEVION S250i, Mercy was able to integrate the addition into the existing radiation oncology department, enabling the hospital to share existing resources and maintain a full continuum of care for patients.

A ribbon-cutting event was held on June 30 with members from Mercy and Mevion Medical Systems.

"We know patients have choices when it comes to cancer care and when they choose Mercy, we want them to know they have access to all the options for care," said Dr. Robert Frazier, division chief of radiation oncology at Mercy Hospital St. Louis. "Each patient is unique so no two treatment plans will be the same. At the David C. Pratt Cancer Center, we now have all the most advanced radiation therapy technologies, both Cyberknife and proton therapy, making sure we offer what's best for each individual during their cancer therapy."

The center features Mevion's industry-leading HYPERSCAN® pencil beam scanning technology and Adaptive Aperture® pMLC. The powerful duo delivers faster and more precise, therapeutic doses of radiation to tumors while preserving surrounding healthy tissue and organs at risk, making proton therapy an ideal treatment choice for tumors near sensitive parts of the body such as the head and neck, spinal cord, breasts, esophagus, prostate, lung, bone, gastrointestinal, stomach, colon, and bladder.

The MEVION S250i system at Mercy also integrates the CBCT imaging system and the C-RAD Catalyst PT surface-guided tracking system, enabling a cutting-edge Image-Guided Proton Therapy configuration for high-precision patient positioning and intra-fraction motion management.

"We congratulate Mercy for starting treatment with the Mevion proton therapy system," said Tina Yu, chief executive officer and president of Mevion Medical Systems. "Mevion is proud to be a part of Mercy's dedication to offering this state-of-the-art cancer treatment in St. Louis and the surrounding area."

Mevion is the system provider for 60% of the clinical single-room proton centers in the U.S. and has treated over 7,000 patients worldwide.

About Mevion Medical Systems
Since 2004, Mevion Medical Systems has been the leading provider of compact proton therapy systems for cancer care. Dedicated to advancing the design and accessibility of proton therapy worldwide, Mevion was the first company to innovate this new single-room platform and continues to further the science and application of proton therapy. Mevion's flagship product, the MEVION S250i Proton Therapy System with HYPERSCAN pencil beam scanning, is the world's smallest proton therapy system that eliminates the obstacles of size, complexity, and cost that exists with other proton therapy systems. Mevion is headquartered in Littleton, Massachusetts, with a presence in Europe and Asia. For more information, please visit www.mevion.com.

Follow us on Twitter: @MevionMedical

Connect with us on LinkedIn: Mevion Medical Systems

Like us on Facebook: MevionMedical

About Mercy
Mercy, one of the 25 largest U.S. health systems, serves millions annually with nationally recognized quality care and one of the nation's largest Accountable Care Organizations. Mercy is a highly integrated, multi-state health care system including more than 40 acute care, managed and specialty (heart, children's, orthopedic and rehab) hospitals, convenient and urgent care locations, imaging centers and pharmacies. Mercy has 900 physician practices and outpatient facilities, 3,400 Mercy Clinic physicians and advanced practitioners, as well as more than 40,000 co-workers serving patients and families across Arkansas, Kansas, Missouri and Oklahoma. Mercy also has clinics, outpatient services and outreach ministries in Arkansas, Louisiana, Mississippi and Texas.


These press releases may also interest you

at 09:15
Octave® Bioscience, Inc., a leading precision care company that delivers a new standard for managing multiple sclerosis (MS) and other neurodegenerative diseases, today announced the appointment of two key executives, Jeron Evans as Chief Revenue...

at 09:10
BioSkryb Genomics, a company ushering in the next generation of single-cell technology, will highlight how its ResolveDNA and ResolveOME single-cell assays can unravel the complexities of tumor evolution at the American Association for Cancer...

at 09:07
KURU® Footwear, the inventor of heel-first footwear, today unveiled its 2024 Foot Pain Trends Report. Featuring significant industry discoveries and valuable consumer perspectives, KURU's comprehensive and medically reviewed report highlights the...

at 09:05
Personalis, Inc. , a leader in advanced genomics for precision oncology, announced today that a podium talk and multiple abstracts featuring data for the company's NeXT Personal® whole genome-based, tumor-informed assay for ultra-sensitive ctDNA...

at 09:05
...

at 09:04
Canadian-based Noze, a global leader in the breath-based diagnostic space, announced today it received a new grant from the Bill & Melinda Gates Foundation, bringing the foundation's total grant funding to Noze to $1.8 million. The announcement comes...



News published on and distributed by: